42 results about "Bacterial Conjunctivitis" patented technology

The invention discloses azithromycin gel eye drops and a preparation process thereof. The eye drops are prepared from a main medicine, namely azithromycin and excipients such as an adhesive, a gel matrix, an isotonic regulator, a preservative, an antioxidant, a buffering agent and the like. The adhesive, namely polycarbophil in the eye drops can increase the biological adhesion of the eye drops, so that the detention time of medicines in eyes is further prolonged. The invention provides a practical, convenient and reliable ophthalmic preparation for treating bacterial conjunctivitis, and solves the problems that the detention time of medicines in an eye drop formulation in the eyes is short, the medicines are not easy to absorb, the bioavailability is low and the like.

An eyedrops able to become gel after it is dropped in eye for treating bacterial conjuctivities, keratitis, keratohelcosis, dacryocystitis, etc is prepared from antibacterial infilammatino-relieving medicine, thickening agent, antiseptic, isotonic regulator, pH regulator and water. Its advantages are long stay time in eye, high curative effect, and low poison and irritation.

The eye drop is prepared with bear bile powder as medicine material and phosphate solution as buffering agent. It has the functions of bacteriostasis, resisting virus, strengthening eyesight, clearing away heat, etc. It is used in treating acute bacterial conjunctivitis, epidemic viral keratitis and has high curative effect and short treating period.

The Gatifloxacin gel preparation for external use and eye use has Gatifloxacin as main component and its supplementary material includes chitosan as gel substrate, iso-osmotic regulator, pH regulator, preservative, injection water, etc. The preparation has Gatifloxacin content of 0.1-3 wt% and chitosan content of 0.3-3 wt%. It has obvious anti-infection function and functions of speeding heal of wound, promoting epidermal growth, inhibiting formation of scar tissue, maintaining local medicine density for long term, etc. It is used in treating burns, scalds, skin infection, folliculitis, bacterial conjunctivitis, keratitis, etc.

The invention discloses a Chinese medicinal composition for treating conjunctivitis, belonging to the technical field of Chinese medicines. The Chinese medicinal composition is prepared from 15 parts of baikal skullcap root, 6 parts of honeysuckle flower, 10 parts of divaricate saposhnikovia root, 10 parts of virgate wormwood herb, 10 parts of szechuan lovage rhizome, 20 parts of dandelion, 20 parts of cicada shell, 10 parts of gentian, 5 parts of white paeony root, 5 parts of mint and 10 parts of liquoric root. The Chinese medicinal composition has good treatment effects on the aspect of treatment of inflammatory conjunctivitis, bacterial conjunctivitis, viral conjunctivitis and allergic conjunctivitis, and has a remarkable clinical popularization value.

The invention discloses lomefloxacin hydrochloride eye drops and a preparation method and application thereof. The lomefloxacin accounts for 0.3% of the active components. The preparation also comprises a tackifier, a buffer salt system, a wetting agent, an isoosmotic adjusting agent, a pH adjusting agent and a bacteriostatic agent, and is suitable for treating the external eye infections such asacute and chronic bacterial conjunctivitis, blepharitis, hordeolum, meibomiantis, dacryocystitis, keratitis, keratohelcosis and the like caused by sensitive pathogenic bacteria. The product is characterized in that: by adding the sodium hyaluronate with a tackifying effect and a moisturizing effect, the viscosity of the lomefloxacin hydrochloride eye drops is improved, the fluidics property thereof is changed, the residence time of the eye drops in the eyes is prolonged, the sufficient absorption of the medicine is ensured, the bioavailability is increased, the administration times are reduced, the compliance of a patient is improved, and an effective treatment effect is realized.

A method for rapidly detecting infectious conjunctivitis in a host is provided. The method includes contacting an ocular test sample with a chromogen (e.g., Reichardt's dye) that exhibits a color change in the presence of a microbe. The present inventors have discovered that the extent of the color change may vary depending on whether the microbe is a bacteria or virus. Without intending to be limited by theory, the present inventors believe that the chromogen interacts with the peptidoglycan-based cell wall structure of bacteria to induce a color change that is even more apparent at infectious levels. It is believed that this interaction occurs to a much greater extent in bacteria than in viruses. Accordingly, although the chromogen may still undergo a color change in the presence of the viruses, it is typically to a much lesser extent. In this manner, the degree of color change of the chromogen may be used in the present invention as a mechanism for differentiating between viral and bacterial conjunctivitis.

The invention relates to slow-released eye drops with azithromycin as an effective ingredient and a preparation method thereof, and aims at solving the problems of poor water solubility of azithromycin and unstable physicochemical property of lipidosome. According to the preparation method, the emulsification evaporation-low-temperature curing method is used to prepare chitosan modified azithromycin solid lipid nanoparticles, so that the stability of lipid nanoparticles in storage is improved, slow release of azithromycin in eyes is also realized, and thus the medicine can fully act to realize the optimal treatment effect. The eye drops are mainly used for treating bacterial conjunctivitis.

Disclosed is a method for treating an ocular inflammatory disease (OID), e.g., uveitis or conjunctivitis, comprising periodic administration of a therapeutically effective amount of laquinimod or a pharmaceutically acceptable salt thereof. Also provided is a pharmaceutical composition comprising laquinimod or a pharmaceutically acceptable salt thereof for use in treating a subject suffering from an OID, uveitis, bacterial conjunctivitis, viral conjunctivitis, an inflammation of the orbital tissue, the lacrimal apparatus, the eyelid, the cornea, the retina or the optic pathway. This application also provides a method for treating a subject suffering from an autoimmune disease-associated ocular inflammation comprising periodic ocular administration to the subject a therapeutically effective amount of laquinimod or a pharmaceutically acceptable salt, and an ocular pharmaceutical composition comprising laquinimod or a pharmaceutically acceptable salt thereof for use in treating an autoimmune disease-associated ocular inflammation.

Polyhexamethylene guanidine eye drops relate to the technical field of eye drops, and comprise the following components by mass: 0.01%-0.1% of polyhexamethylene guanidine hydrochloride, 0.01% of a synergist, 0.1% of pharmaceutical grade hydroxy propyl methyl cellulose, 0.05% of PEG200 (polyethylene glycol), 0.05% of PEG6000, 0.05% of water soluble vitamin E, 0.01% of water-soluble mint, 0.1% of pure sodium chloride, and 99.53%-99.62% of pure water. Polyhexamethylene guanidine is used in the eye drops, and the polyhexamethylene guanidine eye drops are suitable for bacterial conjunctivitis, keratitis, keratohelcosis, dacryocystitis, postoperative infection and other external ocular infections, and is good in sterilization effect, mild in nature, and non-irritating.

The invention belongs to the technical field of medicine product processing, and in particular relates to dendrobe eye drops and a preparation method thereof. The dendrobe eye drops consist of the following components in percentage by mass: 40 to 65 percent of dendrobe, 10 to 23 percent of the root bark of the peony tree, 5 to 8 percent of rhizoma acori graminei, 2 to 10 percent of bighead atractylodes rhizome, 6 to 10 percent of fructus cnidii, 3 to 7 percent of biond magnolia flower, 2 to 5 percent of chitosan, 1 to 3 percent of vitamin B12 powder, 1 to 3 percent of vitamin B1 and 3 to 8 percent of normal saline. The dendrobe eye drops provided by the invention adopts the common traditional Chinese medicine components, is reasonable in compatibility and safe and reliable in medicine, has antibacterial and anti-inflammation effects, has remarkable treatment effect on eye diseases such as bacterial conjunctivitis and keratitis, and has the characteristics of exact curative effect, quick response, high curative ratio, no side effect and the like; and the preparation of the dendrobe eye drops is capable of storing effective components in the raw materials, reasonable in production process and suitable for industrialized production.

Instillation of a 1.5% (w/v) levofloxacin ophthalmic solution three times a day, which is the dosage or dose regimen of the present invention, has features to cure bacterial conjunctivitis in a shorter time than instillation of a 0.5% (w/v) ophthalmic solution three times a day, which is the conventional dosage or dose regimen, and not to increase the rate of occurrence of side effects. Curing the ocular infection in a short time leads to shortening of the duration of exposure of the ocular-infection-causing bacterium to levofloxacin. Therefore, the levofloxacin ophthalmic solution in the dosage or dose regimen of the present invention is eventually expected to suppress emergence of the resistant bacterium resulting from the long-term use of the levofloxacin ophthalmic solution in the conventional dosage or dose regimen. In addition, it is confirmed that the levofloxacin ophthalmic solution in the dosage or dose regimen of the present invention directly inhibits the ocular-infection-causing bacterium such as Staphylococcus aureus from becoming resistant to levofloxacin, which results from the short-term use of the levofloxacin ophthalmic solution in the conventional dosage or dose regimen.

The invention discloses azithromycin eye drops. The azithromycin eye drops are a stable eye preparation which is prepared from azithromycin serving as a main active ingredient and proper auxiliary materials. The long-acting eye drops with mucosa adhesiveness prepared from the latest auxiliary materials at home and abroad have a medicine controlled-release system, the active ingredient stops in eyes for several hours to enhance the antibacterial activity of target tissues, so that the using frequency of the eye drops can be reduced, and the eye drops are convenient to use. The azithromycin eye drops are suitable for treating bacterial conjunctivitis caused by microbial sensitive strains such as G group corynebacterium, haemophilus influenzae, staphylococcus aureus, streptococcus mitis groups and streptococcus pneumoniae.

The invention relates to an ophthalmic composition. The ophthalmic composition comprises moxifloxacin and menthol and/or N-succinyl carboxymethyl chitosan. The invention also relates to a preparation method of the ophthalmic composition, which comprises the following steps: mixing the moxifloxacin, the menthol and/or the N-succinyl carboxymethyl chitosan, the osmotic pressure regulator, the pH regulator, the metal ion chelating agent, the surfactant and the water for injection to obtain the ophthalmic composition. The invention also relates to an application of the ophthalmic composition in preparation of a medicine for treating ocular inflammation, and the ocular inflammation comprises bacterial conjunctivitis caused by gram-positive bacterium and/or gram-negative bacterium infection. As eye drops, the ophthalmic composition provided by the invention not only can improve the treatment effect on bacterial conjunctivitis of a patient, but also can avoid adverse effects such as eye stimulation, conjunctival congestion and edema after administration, so that the administration compliance of the patient is improved, and the recovery time of the patient is shortened.

The invention relates to an eye use Enoxacin slow release gelling agent and its preparation method, which comprises the following constituents (by weight proportions), Enoxacin 0.1-1, and thickening agent 0.1-40, preservative agent 0.001-3, isotonic conditioning agent 0.1-10, pH=4.5-9 of pH modifier, and balancing water. The preparation process comprises dissolving the Enoxacin into water, adding thickening agent and stewing, charging preservative agent, isotonic conditioning agent, stirring to dissolve, regulating pH=4.5-9 with pH modifier, subjecting the solution to filtration by microporous filtering film, watering to total amount from the filter.

The invention discloses traditional Chinese medicine eye drops, and relates to the technical field of eye drops. The traditional Chinese medicine eye drops consist of the following raw materials: 15-25 parts of ofloxacin and 10-20 parts of borneol flake-like crisp crystals as main components, and 3-6 parts of mannitol, 5-8 parts of disodium edetate and 2-5 parts of benzalkonium bromide as auxiliary materials, and the raw materials and the auxiliary materials are mixed and processed to form the traditional Chinese medicine eye drops. By selecting natural medicines and aiming at etiology and pathogenesis of bacterial infection such as bacterial conjunctivitis, bacterial keratitis, pinkeye and bacterial endophthalmitis caused by sensitive bacteria, all the medicinal materials have respectiveeffects and are mutually coordinated, common traditional Chinese medicine components are adopted, the raw materials are easy to obtain and low in price, the medicines are safe and reliable, and the effects of resisting bacteria, diminishing inflammation and the like are achieved. The traditional Chinese medicine eye drops have a remarkable treatment effect on bacterial infection eye diseases suchas bacterial conjunctivitis, bacterial keratitis, pinkeye and bacterial endophthalmitis, and have the characteristics of being exact in curative effect, quickly taking effect, and being high in cure rate, no side effect and the like.